Using Specific Steroid Molecules to Block Salt Retention in the Body

A 1976 medical patent describing the use of 11-beta,18-oxidopregnane compounds to help the body excrete sodium by blocking the salt-retaining effects of the hormone aldosterone.

What it covers

This patent details a method for treating patients who retain too much salt by administering specific chemical compounds known as 11-beta,18-oxidopregnanes. These molecules act as aldosterone antagonists, meaning they compete with or block the natural hormone aldosterone, which normally signals the kidneys to hold onto sodium. By inhibiting this hormone, the drug forces the kidneys to excrete more sodium, which can help lower blood pressure or reduce fluid buildup. The claims specify a range of chemical structures, including 18-deoxyaldosterone, that can be used to achieve this effect.

What it doesn't cover

• —Does not cover the use of spironolactone or other non-oxidopregnane class diuretics.
• —Does not cover treatments for conditions unrelated to mineralocorticoid-induced sodium retention.
• —Does not claim the synthesis process for creating these specific chemical compounds.

The clever bit

The invention identifies that by modifying the 11-beta,18-oxido structure of the pregnane backbone, one can create a molecule that binds to the aldosterone receptor without triggering the same salt-retaining response as the hormone itself.

Why it matters

This patent represents an early effort to pharmacologically manage fluid balance by targeting the mineralocorticoid pathway. While aldosterone antagonists are now a standard class of drugs for heart failure and hypertension, this patent highlights the foundational exploration of steroid-based molecules to modulate kidney function.

Real-world examples

• 1.Experimental diuretic therapies
• 2.Research into mineralocorticoid receptor antagonists